[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201370063A1 - Фосфолипидом рака - Google Patents

Фосфолипидом рака

Info

Publication number
EA201370063A1
EA201370063A1 EA201370063A EA201370063A EA201370063A1 EA 201370063 A1 EA201370063 A1 EA 201370063A1 EA 201370063 A EA201370063 A EA 201370063A EA 201370063 A EA201370063 A EA 201370063A EA 201370063 A1 EA201370063 A1 EA 201370063A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
diagnosing
derived
analysis
phospholypide
Prior art date
Application number
EA201370063A
Other languages
English (en)
Inventor
Йоханнес Виктор Мария Свиннен
Йелле Махилс
Эйра Мари-Йеанне Эдел Леопольд Марин
Муралидхара Рао Багади
Original Assignee
Католике Университейт Лёвен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/051936 external-priority patent/WO2011098509A1/en
Application filed by Католике Университейт Лёвен filed Critical Католике Университейт Лёвен
Publication of EA201370063A1 publication Critical patent/EA201370063A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

В целом, изобретение относится к идентификации липидомных биомаркеров для анализа на рак и обеспечивает прогностические и предиктивные способы и наборы для диагностики и субтипирования рака и для диагностики и/или прогнозирования развития опухоли и ее ответа на нацеленную на липидный метаболизм или другие типы терапии у субъекта путем применения анализа фосфолипидного профиля, при котором признаками фенотипа удлинения служат изменения объединенной длины ацильных цепей интактных видов фосфолипидов, полученных из биологических жидкостей или полученных из опухоли.
EA201370063A 2010-09-24 2011-09-23 Фосфолипидом рака EA201370063A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1016139.6A GB201016139D0 (en) 2010-09-24 2010-09-24 Cancer phosholipidome
PCT/EP2011/051936 WO2011098509A1 (en) 2010-02-11 2011-02-10 Phospholipid profiling and cancer
PCT/EP2011/066568 WO2012038525A1 (en) 2010-09-24 2011-09-23 Cancer phospholipidome

Publications (1)

Publication Number Publication Date
EA201370063A1 true EA201370063A1 (ru) 2013-08-30

Family

ID=43127956

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370063A EA201370063A1 (ru) 2010-09-24 2011-09-23 Фосфолипидом рака

Country Status (6)

Country Link
US (1) US9400274B2 (ru)
CN (1) CN103119447A (ru)
BR (1) BR112013006528A2 (ru)
EA (1) EA201370063A1 (ru)
GB (1) GB201016139D0 (ru)
WO (1) WO2012038525A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9164084B2 (en) 2012-01-31 2015-10-20 Purdue Research Foundation Methods for determining aggressiveness of a cancer and treatment thereof
WO2015085225A1 (en) * 2013-12-06 2015-06-11 Hector De Leon Lipid biomarker signatures for lung injury diagnosis
WO2016051020A1 (en) 2014-10-02 2016-04-07 Zora Biosciences Oy Methods for detecting ovarian cancer
EP3307243A4 (en) * 2015-06-09 2019-01-02 The Board of Regents of The University of Texas System Diagnostic test for early stage cancer
CN106802334A (zh) * 2015-11-26 2017-06-06 中国医学科学院基础医学研究所 一组监测癌症疾病进展和或耐药性产生的个体化标志物
EP3427066A4 (en) * 2016-03-10 2020-02-19 Agency for Science, Technology and Research LIPID BIOMARKERS FOR CANCER DIAGNOSIS
CN106526028A (zh) * 2016-11-14 2017-03-22 中国药科大学 代谢标志物在诊断鉴别甲状腺良恶性病变中的应用
CN106770873B (zh) * 2017-01-19 2019-02-19 中国人民解放军第四军医大学 一种膀胱癌诊断标志物及其应用和诊断试剂盒
US20180246112A1 (en) * 2017-02-28 2018-08-30 University Of Kentucky Research Foundation Biomarkers of Breast and Lung Cancer
CN108872578B (zh) * 2017-05-11 2021-07-02 首都医科大学附属北京口腔医院 一种诊断和监测口腔癌的新方法
EP3649472A1 (en) 2017-07-05 2020-05-13 Zora Biosciences OY Methods for detecting ovarian cancer
CN109212216B (zh) * 2018-10-31 2019-07-09 中国药科大学 对羟基肉桂酸或磷脂酰乙醇胺在大肠癌早期诊断方面的应用
WO2020163581A1 (en) * 2019-02-06 2020-08-13 Berg Llc Markers for the diagnosis of biochemical recurrence in prostate cancer
KR102156217B1 (ko) * 2019-03-05 2020-09-15 연세대학교 산학협력단 대장암 진단용 지질 바이오마커 및 이의 용도
WO2020182995A1 (en) * 2019-03-14 2020-09-17 Universität Heidelberg Vlcfa-containing lipids as prognostic and predictive marker for cancer therapies
AU2020287121A1 (en) * 2019-06-04 2022-01-06 Avanti Polar Lipids, Llc Universal lipid quantitative standards for use in lipidomics
CN116027041B (zh) * 2023-01-13 2023-12-05 郑州大学第一附属医院 口腔癌辅助诊断标志物、试剂盒及其应用
CN117388495B (zh) * 2023-12-13 2024-02-09 哈尔滨脉图精准技术有限公司 用于诊断肺癌分期的代谢标志物的应用及试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010005550A (ko) * 1997-03-21 2001-01-15 아타르진 테크놀로지스 인코퍼레이티드 리소포스포리피드 농도 변화와 연관된 암 감지 방법
US6248553B1 (en) * 1998-10-22 2001-06-19 Atairgin Technologies, Inc. Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US8067153B2 (en) * 2005-07-27 2011-11-29 Oncotheraphy Science, Inc. Genes and polypeptides relating to prostate cancers
EP2002262B1 (en) * 2006-03-15 2016-06-22 The General Hospital Corporation Devices and methods for detecting cells and other analytes
JP5778185B2 (ja) 2010-02-11 2015-09-16 カトリーケ・ウニベルシタイト・リユーベン リン脂質プロファイリング及びガン

Also Published As

Publication number Publication date
WO2012038525A1 (en) 2012-03-29
US20140220613A1 (en) 2014-08-07
GB201016139D0 (en) 2010-11-10
CN103119447A (zh) 2013-05-22
US9400274B2 (en) 2016-07-26
BR112013006528A2 (pt) 2016-08-02

Similar Documents

Publication Publication Date Title
EA201370063A1 (ru) Фосфолипидом рака
IN2013CN01129A (ru)
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
BR112012011230A2 (pt) fatores de risco e previsão de infarto do miocárdio
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
EA201270020A1 (ru) Определение риска развития атеросклеротической болезни сердца
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR THE DIAGNOSIS OF A DISEASE
WO2011161062A3 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
ATE554389T1 (de) Apex als marker für lungenkrebs
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
CY1117838T1 (el) Παραγοντες προβλεψης για θεραπευτικη αγωγη καρκινου
AR083357A1 (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
BRPI0606685A2 (pt) anticorpos gitr para o diagnóstico de nsclc
MX2019006098A (es) Ensayo de anticuerpos.
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
NZ729773A (en) Biomarkers for disease progression in melanoma
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma